Now on
Cystic fibrosis: Orphan drug designation to counter lung inflammation
The European Medicines Agency (EMA) has granted Orphan Drug Designation for cystic fibrosis to GY971, a new anti-inflammatory molecule developed by the Universities of Ferrara and Padua and the Azienda Ospedaliera Universitaria di Verona with funding from the Foundation for Cystic Fibrosis Research - ETS (FFC Ricerca).
Rare Partners e il premio Chiara Gemmo
Nasce il Premio Chiara Gemmo dedicato ai giovani ricercatori. L’iniziativa si propone di sostenere le nuove generazioni di scienziati.
[E]Motion: noimuoviAMOlaricerca
[E]Motion: moving research
[E]Motion is the name of the challenging journey that Alessandro, a young man affected by the Usher Syndrome, will make together with Rare Partners, riding his tandem bike “Bike4Usher” in support of research for the Usher Syndrome.
#MiFidoDiTe: quarantaduemila metri a sostegno della ricerca per la Sindrome di Usher.
#MiFidoDiTe: 42 km legati l'uno all'altra: una maratona a nuoto che parte da Vulcano
Inhaled teicoplanin completed phase 1 clinical trial in cystic fibrosis
Inhaled teicoplanin completed phase 1 clinical trial in cystic fibrosis